Immuno Oncology Diagnosis Market Global Report 2026

The immuno oncology diagnosis market size has grown strongly in recent years. It will grow from $13.8 billion in 2025 to $15.15 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rising global cancer incidence rates, increasing adoption of targeted cancer therapies, expansion of hospital based diagnostic laboratories, growing use of immunohistochemistry techniques in oncology, improvements in biomarker discovery technologies.

The immuno oncology diagnosis market size is expected to see strong growth in the next few years. It will grow to $22.16 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing demand for personalized cancer immunotherapy, expansion of liquid biopsy and non invasive diagnostics, rising adoption of ai driven diagnostic platforms, growth in precision medicine and companion diagnostics, increasing investment in oncology research and clinical trials. Major trends in the forecast period include liquid biopsy based immuno-oncology diagnostic assays for early cancer detection and monitoring, multiplex immune profiling platforms for tumor microenvironment characterization, companion diagnostic kits for personalized cancer immunotherapy selection, high sensitivity flow cytometry based immune cell analysis for cancer stratification, ai enabled digital pathology software for immuno-oncology biomarker interpretation.

The rising global burden of cancer is anticipated to drive the growth of the immuno-oncology diagnosis market in the forecast period. Cancer is a medical condition involving the uncontrolled multiplication and progression of abnormal cells, which can infiltrate nearby tissues and metastasize to other areas of the body, affecting normal physiological functions. The incidence of cancer is increasing due to the growing elderly population, as aging contributes to the accumulation of genetic alterations and cellular damage, thereby increasing the likelihood of tumor formation. Immuno-oncology diagnosis facilitates cancer care by supporting biomarker detection, immune system profiling, and precision oncology testing, which are essential for developing personalized and targeted cancer treatment approaches, improving therapeutic effectiveness, patient outcomes, and clinical decision-making. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, global cancer cases were projected to exceed 35 million new cases by 2050, representing a 77% rise compared with the estimated 20 million cases recorded in 2022. Therefore, the increasing global prevalence of cancer is driving the growth of the immuno-oncology diagnosis market.

Key companies operating in the immuno-oncology diagnosis market are focusing on developing innovative solutions, such as AI-enabled multimodal immune profiling tests, to enhance precision cancer diagnosis, improve treatment response prediction, and support personalized immunotherapy decision-making. AI-enabled multimodal immune profiling tests are advanced diagnostic solutions that use artificial intelligence to analyze multiple biological data types, including genomic, proteomic, and immune biomarkers, to evaluate immune system responses and guide personalized cancer treatment decisions. For example, in November 2024, Tempus AI, Inc., a US-based artificial intelligence and precision medicine company, launched the Immune Profile Score (IPS) algorithmic test, an AI-enabled multimodal immune profiling test. It is designed to improve the evaluation of immune response patterns and support more informed immuno-oncology treatment decisions for cancer patients. The IPS test is a multimodal biomarker assay that integrates DNA and RNA sequencing insights with clinical and molecular data to generate a predictive immune response score ranging from 0 to 100.

In July 2025, Alden Scientific, a US-based research institute and health technology company, acquired Oncimmune Germany GmbH for an undisclosed amount. With this acquisition, Alden Scientific intended to reinforce its global position in precision medicine by expanding its expertise in immune profiling, autoantibody biomarker discovery, and multi-omics analytics, while obtaining access to Oncimmune’s ImmunoINSIGHTS platform and its extensive antigen library containing more than 9,000 human and multi-species antigens. Oncimmune Germany GmbH is a Germany-based company providing immuno-oncology diagnostics, with expertise in biomarker discovery, immune profiling, and immunodiagnostic services.

Major companies operating in the immuno oncology diagnosis market report are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Natera Inc., Caris Life Sciences Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Promega Corporation, Takara Bio Inc., Bioneer Corporation, Vazyme Biotech Co. Ltd., Exact Sciences Corporation, Hologic Inc., Becton Dickinson and Company.

North America was the dominating region in the immuno oncology diagnosis market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the immuno oncology diagnosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the immuno oncology diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.